Graham Capital Management’s iTeos Therapeutics ITOS Stock Holding History

Graham Capital Management’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20,637	Closed	-$206K	–	1452
2025 Q2	$206K	Sell	20,637 -20,038	-49%	-$161K	﹤0.01%	1126
2025 Q1	$243K	Buy	40,675 +29,549	+266%	+$217K	﹤0.01%	1067
2024 Q4	$85.4K	Buy	+11,126	New	+$95.6K	﹤0.01%	1169
2024 Q1	–	Sell	-14,276	Closed	-$156K	–	1181
2023 Q4	$156K	Buy	+14,276	New	+$142K	﹤0.01%	871

Other funds holding ITOS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Graham Capital Management's ITOS Position: Q3 2025 in Review

Graham Capital Management sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 20,637 shares — an estimated $206K sold.

Graham Capital Management first reported a position in ITOS in Q4 2023 and held it in 4 quarters. The position peaked at $243K in Q1 2025. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

Graham Capital Management reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
Graham Capital Management sold 20,637 iTeos Therapeutics shares in Q3 2025, an estimated $206K.
Graham Capital Management first reported a position in iTeos Therapeutics in Q4 2023 and held it in 4 quarters.
Graham Capital Management's iTeos Therapeutics position peaked at $243K in Q1 2025.
1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on Graham Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.